Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR-800-EV
- Development stage
- Preclinical
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Topical
01
Overview
IR-800-EV is a fluorescently-labeled derivative of the antibody-drug conjugate enfortumab vedotin (Padcev). It is synthesized by conjugating enfortumab vedotin with the near-infrared fluorescent dye IRDye 800CW using standard NHS ester chemistry. IR-800-EV acts as a targeted optical imaging agent that binds to Nectin-4 (poliovirus receptor-related protein 4), a cell surface marker commonly overexpressed in urothelial (bladder) cancer and other solid tumors. The agent is designed for intra-operative tumor assessment, evaluation of minimal residual disease (MRD), and determination of candidacy for Nectin-4-targeted antibody-drug conjugate therapies.
- Other names
- fluorescently-labeled enfortumab vedotinIRDye 800CW-enfortumab vedotinIRDye800CW-enfortumab vedotinIRDye-800CW-enfortumab vedotinIRDye 800CW-PadcevIRDye800CW-PadcevIRDye-800CW-Padcev
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on IR-800-EV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR-800-EV.